Endothelial dysfunction in metabolic syndrome: prevalence, pathogenesis and management.
| Title | Endothelial dysfunction in metabolic syndrome: prevalence, pathogenesis and management. |
| Publication Type | Journal Article |
| Year of Publication | 2010 |
| Authors | Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. |
| Journal | Nutr Metab Cardiovasc Dis |
| Volume | 20 |
| Issue | 2 |
| Pagination | 140-6 |
| Date Published | 2010 Feb |
| ISSN | 1590-3729 |
| Keywords | Bariatric Surgery, Biological Markers, Cardiovascular Agents, Endothelium, Vascular, Hemodynamics, Humans, Insulin Resistance, Metabolic Syndrome X, Risk Reduction Behavior, Treatment Outcome |
| Abstract | The metabolic syndrome (MetS) is characterized by the presence of central obesity, impaired glucose metabolism, dyslipidemia and hypertension. Several studies showed that MetS is associated with increased risk for type 2 diabetes mellitus (T2DM) and vascular events. All components of MetS have adverse effects on the endothelium. Endothelial dysfunction plays a role in the pathogenesis of atherosclerosis and might also increase the risk for insulin resistance and T2DM. We review the prevalence and pathogenesis of endothelial dysfunction in MetS. We also discuss the potential effects of lifestyle measures and pharmacological interventions on endothelial function in these patients. It remains to be established whether improving endothelial function in MetS will reduce the risk for T2DM and vascular events. |
| DOI | 10.1016/j.numecd.2009.08.006 |
| Alternate Journal | Nutr Metab Cardiovasc Dis |
| PubMed ID | 19833491 |
